This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Serum levels of soluble programmed death-ligand 1 (sPD-L1) in patients with primary central nervous system diffuse large B-cell lymphoma
BMC Cancer Open Access 13 February 2020
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on SpringerLink
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Friedberg JW . Relapsed/Refractory Diffuse Large B-Cell Lymphoma. Hematol Am Soc Hematol Educ Program 2011; 2011: 498–505.
Pedoeem A, Azoulay-Alfaguter I, Strazza M, Silverman GJ, Mor A . Programmed death-1 pathway in cancer and autoimmunity. Clin Immunol 2014; 153: 145–152.
Chen DS, Mellman I . Oncology meets immunology: the cancer-immunity cycle. Immunity 2013; 39: 1–10.
Armand P, Nagler A, Weller EA, Devine SM, Avigan DE, Chen Y-B et al. Disabling immune tolerance by programmed death-1 blockade with pidilizumab after autologous hematopoietic stem-cell transplantation for diffuse large b-cell lymphoma: results of an international phase II trial. J Clin Oncol 2013; 31: 4199–4206.
Rossille D, Gressier M, Damotte D, Maucort-Boulch D, Pangault C, Semana G et al. High level of soluble programmed cell death ligand 1 in blood impacts overall survival in aggressive diffuse large B-cell lymphoma: results from a French multicenter clinical trial. Leukemia 2014; 28: 2367–2375.
Drake MT, Maurer MJ, Link BK, Habermann TM, Ansell SM, Micallef IN et al. Vitamin D insufficiency and prognosis in non-Hodgkin’s lymphoma. J Clin Oncol 2010; 28: 4191–4198.
Wilcox RA, Ristow K, Habermann TM, Inwards DJ, Micallef INM, Johnston PB et al. The absolute monocyte and lymphocyte prognostic score predicts survival and identifies high-risk patients in diffuse large-B-cell lymphoma. Leukemia 2011; 25: 1502–1509.
Proctor MJ, McMillan DC, Morrison DS, Fletcher CD, Horgan PG, Clarke SJ . A derived neutrophil to lymphocyte ratio predicts survival in patients with cancer. Br J Cancer 2012; 107: 695–699.
Ziepert M, Hasenclever D, Kuhnt E, Glass B, Schmitz N, Pfreundschuh M et al. Standard international prognostic index remains a valid predictor of outcome for patients with aggressive CD20+ B-cell Lymphoma in the Rituximab Era. J Clin Oncol 2010; 28: 2373–2380.
Azzaoui I, Uhel F, Rossille D, Pangault C, Dulong J, Le Priol J et al. T-cell defect in diffuse large B-cell lymphomas involves expansion of myeloid-derived suppressor cells. Blood 2016; 128: 1081–1092.
Kwon D, Kim S, Kim P-J, Go H, Nam SJ, Paik JH et al. Clinicopathological analysis of programmed cell death 1 and programmed cell death ligand 1 expression in the tumour microenvironments of diffuse large B cell lymphomas. Histopathology 2015; 68: 1079–1089.
Kiyasu J, Miyoshi H, Hirata A, Arakawa F, Ichikawa A, Niino D et al. Expression of programmed cell death ligand 1 is associated with poor overall survival in patients with diffuse large B-cell lymphoma. Blood 2015; 126: 2193–2201.
Riihijarvi S, Fiskvik I, Taskinen M, Vajavaara H, Tikkala M, Yri O et al. Prognostic influence of macrophages in patients with diffuse large B-cell lymphoma: a correlative study from a Nordic phase II trial. Haematologica 2015; 100: 238–245.
Wada N, Zaki MAA, Hori Y, Hashimoto K, Tsukaguchi M, Tatsumi Y et al. Tumour-associated macrophages in diffuse large B-cell lymphoma: a study of the Osaka Lymphoma Study Group. Histopathology 2012; 60: 313–319.
Scott DW, Gascoyne RD . The tumour microenvironment in B cell lymphomas. Nat Rev Cancer 2014; 14: 517–534.
Acknowledgements
This study is supported by the French Health Minister (BMS_LyTrans project; NCT01287923), the National Institute of Cancer (INCa Translational Research 2010), the French Lymphoma Study Association (LYSA), the French National Agency for Research (ANR Carnot/CALYM), the National Cancer Institute (P50 CA97274, R01 CA92153) and the Henry J Predolin Foundation. Concerning the French cohort, we are indebted to the LYSA pathology platform (Hôpital Henri Mondor, Créteil) for immunohistochemical experiments, and the Centre de Ressources Biologiques CRB-Santé (BB-0033-00056) of the Rennes hospital for providing high-quality samples. This work was partly supported by a French National Cancer Institute post-doctoral fellowship (grant number PDOC-RC-GO/07-003) to the first author (DR).
Author contributions
TF raised the fund. IA did the sPD-L1 measurements. DR did the data analysis. MJM and JRC contributed to the statistics. DR, JRC and TF did the data interpretation and wrote the manuscript. NM designed the parent French study. JRC designed the US study. GL and MP did the French database update and immunohistochemistry. ALF did the immunohistochemistry on the MER cohort. CP did the blood sample collection. IA, ALF, MJM, CP, TMH, SMA, BKL, KT, TEW, TL, SLS, MR and NM contributed to the writing and approving of the manuscript.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no conflict of interest.
Additional information
Supplementary Information accompanies this paper on the Leukemia website
Rights and permissions
About this article
Cite this article
Rossille, D., Azzaoui, I., Feldman, A. et al. Soluble programmed death-ligand 1 as a prognostic biomarker for overall survival in patients with diffuse large B-cell lymphoma: a replication study and combined analysis of 508 patients. Leukemia 31, 988–991 (2017). https://doi.org/10.1038/leu.2016.385
Published:
Issue Date:
DOI: https://doi.org/10.1038/leu.2016.385
This article is cited by
-
Prognostic value of soluble programmed cell death ligand-1 (sPD-L1) in lymphoma: a systematic review and meta-analysis
Annals of Hematology (2023)
-
Safety and efficacy of durvalumab with R-CHOP or R2-CHOP in untreated, high-risk DLBCL: a phase 2, open-label trial
International Journal of Hematology (2022)
-
Serum levels of soluble programmed death-ligand 1 (sPD-L1) in patients with primary central nervous system diffuse large B-cell lymphoma
BMC Cancer (2020)
-
PD-1/PD-L1 expression and interaction by automated quantitative immunofluorescent analysis show adverse prognostic impact in patients with diffuse large B-cell lymphoma having T-cell infiltration: a study from the International DLBCL Consortium Program
Modern Pathology (2019)
-
Checkpoint Inhibitors Hodgkin Lymphoma and Non-Hodgkin Lymphoma
Current Hematologic Malignancy Reports (2018)